Can Lenvatinib be reimbursed by medical insurance? What should I pay attention to during the reimbursement process?

Lenvatinib (Lenvatinib), as a targeted drug used to treat various types of cancer, has been launched in China and is included in medical insurance. When patients purchase the drug in the country, they can reimburse part of the cost through medical insurance, thus reducing their financial burden. The specific medical insurance reimbursement ratio and reimbursement amount will be affected by different regions, hospitals, and individual patient conditions. Therefore, before purchasing drugs, patients are best to learn about relevant policies and detailed cost information from the hospital pharmacy.

During the medical insurance reimbursement process, patients need to pay attention to some key matters. First of all, although lenvatinib has been included in medical insurance, not all hospitals can achieve full reimbursement immediately. The specific reimbursement ratio and procedures may vary according to the patient's region, the specific policies of the hospital, and the drug procurement channel. Therefore, patients are advised to consult the hospital pharmacy for detailed medical insurance reimbursement procedures before purchasing. Secondly, medical insurance reimbursement amounts usually set a certain upper limit, and the reimbursement ratio of different patients may vary depending on the type of medical insurance and insurance status.

Lenvatinib’s medical insurance reimbursement conditions usually include whether the drug’s indications are within the scope of medical insurance payment, and whether the patient meets relevant disease treatment standards, etc. When patients apply for medical insurance reimbursement, they may need to provide corresponding medical records, a list of medical expenses, and a doctor's prescription as the basis for reimbursement. When purchasing drugs, patients also need to ensure that the lenvatinib they purchase is a drug on the medical insurance catalog. Sometimes generic versions of some drugs may not be covered by medical insurance, so patients need to ensure that the drugs they purchase are consistent with the varieties reimbursed by medical insurance.

For those patients who purchase foreign generic drugs, although the price is relatively low, they may not be able to enjoy domestic medical insurance reimbursement. Taking generic drugs in Laos and Bangladesh as an example, the prices of these drugs range from 400 yuan to 900 yuan, which is much cheaper than original drugs. However, since these generic drugs are not within the scope of domestic medical insurance payment, they cannot be reimbursed through medical insurance, and patients must purchase them at their own expense. The price of original research drugs is relatively high, and the selling price in the domestic market is about 3,000yuan. After medical insurance reimbursement, part of the cost that patients need to pay will vary according to the specific reimbursement situation.

Reference materials:https://www.lenvima.com/